PRKCD and metabolic dysfunction-associated steatohepatitis: Further, given that there are key pathophysiological features in human patients with NASH (obesity and whole body insulin resistance) which are not present in the MCD diet model of NASH, it is possible that PKCδ deletion in the context of obesity and whole body insulin resistance may reduce fibrosis.